Low-dose rate brachytherapy with I-125 seeds has an excellent 5-year outcome with few side effects in patients with low-risk prostate cancer

References

• Hinnen KA, Battermann JJ, van Roermund JG, Moerland MA, Jurgenliemk-Schulz IM, Frank SJ, et al. Long-term biochemical and survival outcome of 921 patients treated with I-125 permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2010;76:1433–8.
   PubMed Web of Science ®Google Scholar
• Morris WJ, Keyes M, Spadinger I, Kwan W, Liu M, McKenzie M, et al. Population-based 10-year oncologic outcomes after low-dose-rate brachytherapy for low-risk and intermediate-risk prostate cancer. Cancer 2013;119:1537–46.
   PubMed Web of Science ®Google Scholar
• Giberti C, Chiono L, Gallo F, Schenone M, Gastaldi E. Radical retropubic prostatectomy versus brachytherapy for low-risk prostatic cancer: a prospective study. World J Urol 2009;27:607–12.
   PubMed Web of Science ®Google Scholar
• Rodrigues G, Yao X, Loblaw DA, Brundage M, Chin JL. Evidence-based guideline recommendations on low-dose rate brachytherapy in patients with low- or intermediate-risk prostate cancer. Canadian Urological Assoc J = Journal De L'Association Des Urologues Du Canada 2013;7:E411–16.
   Google Scholar
• Peinemann F, Grouven U, Bartel C, Sauerland S, Borchers H, Pinkawa M, et al. Permanent interstitial low-dose-rate brachytherapy for patients with localised prostate cancer: a systematic review of randomised and nonrandomised controlled clinical trials. Eur Urol 2011;60:881–93.
   PubMed Web of Science ®Google Scholar
• Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 2015;33:272–7.
   PubMed Web of Science ®Google Scholar
• Bul M, Zhu X, Valdagni R, Pickles T, Kakehi Y, Rannikko A, et al. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol 2013;63:597–603.
   PubMed Web of Science ®Google Scholar
• Stock RG, Stone NN, Tabert A, Iannuzzi C, DeWyngaert JK. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 1998;41:101–8.
   PubMed Web of Science ®Google Scholar
• Nath R, Anderson LL, Luxton G, Weaver KA, Williamson JF, Meigooni AS. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine. Medical Phys 1995;22:209–34.
   PubMed Web of Science ®Google Scholar
• Ash D, Al-Qaisieh B, Bottomley D, Carey B, Joseph J. The correlation between D90 and outcome for I-125 seed implant monotherapy for localised prostate cancer. Radiother Oncol J Eur Soc Therap Radiol Oncol 2006;79:185–9.
   PubMed Web of Science ®Google Scholar
• Shiraishi Y, Yorozu A, Ohashi T, Toya K, Saito S, Nishiyama T, et al. A dose-response analysis of biochemical control outcomes after (125)I monotherapy for patients with favorable-risk prostate cancer. Int J Radiat Oncol Biol Phys 2014;90:1069–75.
   PubMed Web of Science ®Google Scholar
• Stock RG, Stone NN, Cesaretti JA, Rosenstein BS. Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys 2006;64:527–33.
   PubMed Web of Science ®Google Scholar
• Stone NN, Potters L, Davis BJ, Ciezki JP, Zelefsky MJ, Roach M, et al. Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes. Int J Radiat Oncol Biol Phys 2007;69:1472–7.
   PubMed Web of Science ®Google Scholar
• Stone NN, Stock RG, Cesaretti JA, Unger P. Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes. Int J Radiat Oncol Biol Phys 2010;76:355–60.
   PubMed Web of Science ®Google Scholar
• Morris WJ, Spadinger I, Keyes M, Hamm J, McKenzie M, Pickles T. Whole prostate D90 and V100: a dose-response analysis of 2000 consecutive (125)I monotherapy patients. Brachytherapy 2014;13:32–41.
   PubMed Web of Science ®Google Scholar
• Morris WJ, Keyes M, Palma D, McKenzie M, Spadinger I, Agranovich A, et al. Evaluation of dosimetric parameters and disease response after 125 iodine transperineal brachytherapy for low- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2009;73:1432–8.
   PubMed Web of Science ®Google Scholar
• Dasu A, Toma-Dasu I. Prostate alpha/beta revisited – an analysis of clinical results from 14 168 patients. Acta Oncology 2012;51:963–74.
   PubMed Web of Science ®Google Scholar
• Nickers P, Hermesse J, Deneufbourg J-M, Vanbelle S, Lartigau E. Which α/β ratio and half-time of repair are useful for predicting outcomes in prostate cancer? Radiother Oncol 2010;97:462–6.
   PubMed Web of Science ®Google Scholar
• Fowler J, Chappell R, Ritter M. Is α/β for prostate tumors really low? Int J Radiat Oncol Biol Phys 2001;50:1021–31.
   PubMed Web of Science ®Google Scholar
• Keyes M, Miller S, Pickles T, Halperin R, Kwan W, Lapointe V, et al. Late urinary side effects 10 years after low-dose-rate prostate brachytherapy: population-based results from a multiphysician practice treating with a standardized protocol and uniform dosimetric goals. Int J Radiat Oncol Biol Phys 2014;90:570–8.
   PubMed Web of Science ®Google Scholar
• Emara AM, Chadwick E, Nobes JP, Abdelbaky AM, Laing RW, Langley SE. Long-term toxicity and quality of life up to 10 years after low-dose rate brachytherapy for prostate cancer. BJU Int 2012;109:994–1000.
   PubMed Web of Science ®Google Scholar
• Bottomley D, Ash D, Al-Qaisieh B, Carey B, Joseph J, St Clair S, et al. Side effects of permanent I125 prostate seed implants in 667 patients treated in Leeds. Radiother Oncol J Eur Soc Therap Radiol Oncol 2007;82:46–9.
   PubMed Web of Science ®Google Scholar
• Machtens S, Baumann R, Hagemann J, Warszawski A, Meyer A, Karstens JH, et al. Long-term results of interstitial brachytherapy (LDR-Brachytherapy) in the treatment of patients with prostate cancer. World J Urol 2006;24:289–95.
   PubMed Web of Science ®Google Scholar
• Snyder KM, Stock RG, Buckstein M, Stone NN. Long-term potency preservation following brachytherapy for prostate cancer. BJU Int 2012;110:221–5.
   PubMed Web of Science ®Google Scholar
• Matsushima M, Kikuchi E, Maeda T, Nakashima J, Sugawara A, Ando T, et al. A prospective longitudinal survey of erectile dysfunction in patients with localized prostate cancer treated with permanent prostate brachytherapy. J Urol 2013;189:1014–18.
   PubMed Web of Science ®Google Scholar